ABSTRACT
Importance The incidence and severity of coronavirus disease 19 (COVID-19) is higher in men. Sex hormones potentially offer one explanation for differences by sex.
Objective To determine whether men exposed to androgen deprivation therapy (ADT) have lower incidence and severity of COVID-19.
Design We conducted an observational study of male Veterans treated in the Veterans Health Administration from February 15th to July 15th, 2020. We developed a propensity score model to predict the likelihood to undergo Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing. We performed multivariable logistic regression modeling adjusted with inverse probability weighting to examine the relationship between ADT and COVID-19 incidence. We conducted logistic regression analysis among COVID-19 patients to test the association between ADT and COVID-19 severity.
Setting The U.S. Department of Veterans Affairs
Participants The study sample consisted of 6,250,417 male Veterans who were alive as of February 15, 2020.
Exposure Exposure to ADT was defined as having any prescription for a luteinizing hormone releasing hormone analogue or an antiandrogen in the six months prior to the index date.
Main Outcomes and Measures To assess incidence, we used a binary variable indicating any positive reverse transcriptase polymerase chain reaction SARS-CoV-2 test result through July 15, 2020. To measure severity, we constructed a binary variable indicating whether a patient was admitted to the intensive care unit, placed on mechanical ventilation, or dead in the 60 days following a positive test up to July 15, 2020.
Results We identified 246,087 patients who had been tested for SARS-CoV-2, of whom 3,057 were exposed to ADT, and 36,096 patients with cancer and no ADT exposure. Of these, 295 ADT patients and 2,427 other cancer patients had COVID-19 illness. In the primary, propensity-weighted comparison of ADT patients to cancer patients not on ADT, ADT was associated with decreased likelihood of testing positive for SARS-CoV-2 (adjusted OR, 0.88 [95% CI, 0.81-0.95]; p=0.001). ADT was associated with fewer severe COVID-19 outcomes (OR 0.72 [95% CI 0.53-0.96]; p=0.03).
Conclusions and Relevance ADT is associated with reduced incidence and severity of COVID-19 amongst male Veterans. Repurposing of drugs that modulate androgen production and/or action may represent viable potential treatments for COVID-19.
Question Does androgen deprivation therapy (ADT) lower incidence and severity of COVID-19?
Findings In this observational study of male Veterans treated in the Veterans Healthcare System, ADT was associated with decreased likelihood of testing positive for SARS-CoV-2 (adjusted OR, 0.88 [95% CI, 0.81-0.95]; p=0.001). ADT was also associated with fewer severe COVID-19 outcomes (OR 0.72 [95% CI 0.53-0.96]; p=0.03).
Meaning The use of androgen deprivation therapy may be protective against SARS-CoV-2 infection and modulate severity of COVID-19 outcomes.
Competing Interest Statement
Disclosures: SL reports equity in Gilead Sciences, Inc. SLD reports research grants from the following for-profit organizations outside this submitted work: Alnylam Pharmaceuticals Inc., AbbVie Inc., Astellas Pharma Inc., AstraZeneca Pharmaceuticals LP, Biodesix, Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG, and Parexel International Corporation through the University of Utah or Western Institute for Veteran Research.
Funding Statement
Funding: Funding for this study was provided by the US Department of Veterans Affairs (VA), Veterans Health Administration, Cooperative Studies Program, grant number 825 MS DI 33848, and used resources and facilities at the VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13 457. Dr. Rettig is supported by The Prostate Cancer Foundation (PCF) David Geffen Precision Oncology Center of Excellence of VAGLAHS and a Department of Veterans Affairs Merit Review Award. Drs. Becker and Makarov are supported by The John and Daria Barry Precision Oncology Center of Excellence of the VANYHHS, and Edward Blank and Sharon Cosloy Blank Family Foundation. Dr. Becker is supported by VA Career Development Award (CDA 16 206). Dr. Makarov is a Prostate Cancer Foundation Young Investigator Awardee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the VA Central Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: Funding for this study was provided by the US Department of Veterans Affairs (VA), Veterans Health Administration, Cooperative Studies Program, grant number 825-MS-DI-33848, and used resources and facilities at the VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457. Dr. Rettig is supported by The Prostate Cancer Foundation (PCF) David Geffen Precision Oncology Center of Excellence of VAGLAHS and a Department of Veterans Affairs Merit Review Award. Drs. Becker and Makarov are supported by The John and Daria Barry Precision Oncology Center of Excellence of the VANYHHS, and Edward Blank and Sharon Cosloy–Blank Family Foundation. Dr. Becker is supported by VA Career Development Award (CDA 16-206). Dr. Makarov is a Prostate Cancer Foundation Young Investigator Awardee.
The views expressed are those of the authors and do not necessarily represent the views or policy of the Department of Veterans Affairs or the United States Government.
Disclosures: SL reports equity in Gilead Sciences, Inc. SLD reports research grants from the following for-profit organizations outside this submitted work: Alnylam Pharmaceuticals Inc., AbbVie Inc., Astellas Pharma Inc., AstraZeneca Pharmaceuticals LP, Biodesix, Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG, and Parexel International Corporation through the University of Utah or Western Institute for Veteran Research.
Data Availability
We used the Corporate Data Warehouse (CDW) of the VHA, a national data repository that provides access to the electronic health records of all individuals who received care in the VHA. In addition, we drew from the VA COVID-19 Shared Data Resource (CSDR), a newly developed data domain that consists of a wide range of information related to COVID-19 available for all patients who received a COVID-19 laboratory test within VHA or whose positive test result outside VHA was recorded in VHA clinical notes.
